Letter to the editor: Oral antivirals in treatment‐naïve chronic hepatitis C infection
Ankur Jindal – 4 January 2022
Canopy Homolog 2 contributes to liver oncogenesis by promoting unfolded protein response–dependent destabilization of tumor protein P53
Feng Hong, Ching Ying Lin, Jingyue Yan, Yizhou Dong, Yuli Ouyang, Doyeon Kim, Xiaoli Zhang, Bei Liu, Shaoli Sun, Wei Gu, Zihai Li – 4 January 2022
Development of Alcohol‐Associated Hepatitis Is Associated With Specific Changes in Gut‐Modified Bile Acids
Mark D. Muthiah, Ekaterina Smirnova, Puneet Puri, Naga Chalasani, Vijay H. Shah, Calvin Kiani, Stephanie Taylor, Faridoddin Mirshahi, Arun J. Sanyal – 3 January 2022 – The perturbations in bile acids (BAs) in alcohol‐associated hepatitis (AH) and its relationship to disease severity is not well defined. The aims of this study were to define (1) the effects of heavy alcohol consumption on BAs and related microbiome, (2) the additional changes with AH, and (3) the relationship of these changes to disease severity.
Letter to the editor: The multiple mechanisms of fructose disrupt gut‐liver axis and metabolic regulation
Hsien‐Hui Chung – 3 January 2022
Chronic Activation of LXRα Sensitizes Mice to Hepatocellular Carcinoma
Yang Xie, Runzi Sun, Li Gao, Jibin Guan, Jingyuan Wang, Aaron Bell, Junjie Zhu, Min Zhang, Meishu Xu, Peipei Lu, Xinran Cai, Songrong Ren, Pengfei Xu, Satdarshan P. Monga, Xiaochao Ma, Da Yang, Yulan Liu, Binfeng Lu, Wen Xie – 2 January 2022 – The oxysterol receptor liver X receptor (LXR) is a nuclear receptor best known for its function in the regulation of lipid and cholesterol metabolism. LXRs, both the α and β isoforms, have been suggested as potential therapeutic targets for several cancer types.
Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD
Joana Vieira Barbosa, Scott Milligan, Andrew Frick, Jeremy Broestl, Zobair Younossi, Nezam H. Afdhal, Michelle Lai – 29 December 2021 – Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, and its prevalence continues to rise. Fibrosis‐4 index (FIB‐4) has been shown to be a prognostic marker of liver‐related outcomes in patients with NAFLD. We analyzed data from TriNetX global federated research network, combining data on 30 million patients.
George Budd and His Contribution to the Early History of Amyloid Disease
Edward Richard Howard – 28 December 2021
George Budd and His Contribution to the Early History of Amyloid Disease
Edward Richard Howard – 28 December 2021
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis
Elisa Pose, Elsa Solà, Juan J. Lozano, Adrià Juanola, Julia Sidorova, Giacomo Zaccherini, Koos Wit, Frank Uschner, Marta Tonon, Konstantin Kazankov, Cesar Jiménez, Daniela Campion, Laura Napoleone, Ann T. Ma, Marta Carol, Manuel Morales‐Ruiz, Carlo Alessandria, Ulrich Beuers, Paolo Caraceni, Claire Francoz, François Durand, Rajeshwar P. Mookerjee, Jonel Trebicka, Victor Vargas, Salvatore Piano, Hugh Watson, Juan G. Abraldes, Patrick S. Kamath, Mark M.
The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis
Hamish Innes, Hans Dieter Nischalke, Indra Neil Guha, Karl Heinz Weiss, Will Irving, Daniel Gotthardt, Eleanor Barnes, Janett Fischer, M. Azim Ansari, Jonas Rosendahl, Shang‐Kuan Lin, Astrid Marot, Vincent Pedergnana, Markus Casper, Jennifer Benselin, Frank Lammert, John McLauchlan, Philip L. Lutz, Victoria Hamill, Sebastian Mueller, Joanne R. Morling, Georg Semmler, Florian Eyer, Johann von Felden, Alexander Link, Arndt Vogel, Jens U.